Introduction
Current medical advances have resulted in an increase in human life span and a commensurate increase in the elderly population. However, increased longevity has been accompanied by an elevated emergence of conditions of the elderly, including frailty, characterized by declining organ function and physical performance. It is thought that the decrease in pituitary growth hormone (GH) with age might be a contributing factor and that maintenance of GH could be beneficial in the treatment of frailty in the elderly population (Lamberts et al., 1997) . To elicit the biological episodic profile of GH, the development of synthetic peptide GH secretagogues is considered a viable approach to the augmentation of GH secretion (Smith, 2005) .
2-Methylalanyl-N-{1-[(1R)-1-(4-fluorophenyl)-1-methyl-2-oxo-2-pyrrolidin-1-ylethyl]-1H-imidazol-4-yl}-5-phenyl-D-norvalinamide (LY654322) (Fig. 1) is a GH secretagogue, and in vivo pharmacokinetic and metabolism studies were conducted as part of late-stage discovery studies in rats and dogs. The objectives of these studies were to characterize the pharmacokinetics of the parent drug and to delineate major clearance pathways. LY654322 was cleared by renal excretion and hepatic metabolism. Sixteen metabolites were identified altogether and derived from pathways that involved C-oxidation, N-oxidation, and amide hydrolysis. Among these metabolites was M25, which was structurally unique and appeared to be the result of the fusion of two substructures of the parent molecule around an aromatic core. Given its novelty, the characterization of M25 was considered worthwhile. This report describes the identification, urinary disposition, and proposed formation of M25. tion, respectively. Animals were dosed after an overnight fast. Food was restored 2 h postdose, and free access to water occurred throughout.
Sample Collection. Blood samples were collected in heparinized containers on ice, and plasma was harvested by centrifugation. Plasma, urine, and feces samples were stored at Ϫ70°C before analysis.
Rat Studies. To determine plasma pharmacokinetics, three rats were administered LY654322 by tail vein at 3 mg/kg or oral gavage at 30 mg/kg. Blood was sampled from the jugular vein of rats at 0.05 and 0.25 (intravenous only) and 1, 2, 3, 4, 6, 8, and 10 h postdose. To determine urinary metabolites, three rats were housed in metabolism cages. Urine was collected at 0 to 24 h and 24 to 48 h. Dog Studies. To determine plasma pharmacokinetics, three dogs were administered LY654322 by cephalic vein at 1 mg/kg or oral gavage at 3 mg/kg.
Blood was sampled from the jugular vein of dogs at 0.05 and 0.25 (intravenous only) and 1, 2, 3, 4, 6, 8, 10 , and 24 h postdose. To determine urinary metabolites, two dogs were administered LY654322 at 20 mg/kg by oral capsule and housed in metabolism cages. Urine was collected for 0 to 24 h.
In Vitro Studies. Hepatocytes. Cryopreserved hepatocytes (In Vitro Technologies, Baltimore, MD) were incubated (1 million cells/incubation) in Hepatocyte Maintenance Medium (Lonza Walkersville, Inc., Walkersville, MD) containing 50 M LY654322. Conditions were maintained at 37°C in a 5% CO 2 atmosphere. Control incubations without hepatocytes or without substrate were conducted in each study. After 4 h, incubations were sonicated, frozen on dry ice, and stored at Ϫ70°C until analysis.
Liver slices. Rat and dog liver slices (two slices per incubation) of approximately 8 mm in diameter and 200 to 250 m in thickness were incubated in Waymouth's 752/1 medium (Cell and Molecular Technologies, Lavallette, NJ) containing 50 M LY654322. Conditions were maintained at 37°C in a 95% O 2 -5% CO 2 atmosphere. Control incubations without slices or without substrate were conducted in each study. After 24 h, incubations were sonicated, frozen on dry ice, and stored at Ϫ70°C until analysis.
Equipment and Analytical Conditions. Quantitation of LY654322. LC-MS/MS quantitation of LY654322 in rat and dog plasma was performed on a Sciex API 3000 mass spectrometer (Applied Biosystems, Foster City, CA) by monitoring for MH ϩ with the ion transition m/z 563.4 to 192.4. Plasma samples were extracted by mixing with a 2ϫ volume of acetonitrile, centrifuged, and introduced into the mass spectrometer source with a Metachem Monochrom C18 column (2.1 ϫ 50 mm; 5 m) using a combination of mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in methanol) at a flow rate of 350 l/min. Mobile phase B was delivered as a gradient from 20 to 75% over 0.8 min and restored to 20% at 0.9 min. The 
METABOLISM OF LY654322 TO AN UNUSUAL DIIMIDAZOPYRIDINE
at ASPET Journals on June 6, 2017 dmd.aspetjournals.org calibration range was 3.9 to 4000 ng/ml. Samples above the limit of quantification were diluted and reanalyzed to yield results within the calibration range.
Pharmacokinetic analysis. The pharmacokinetic parameters of LY654322 in plasma were calculated by a noncompartmental method using WinNonlin. The terminal half-life (t 1/2 ) was calculated from the first-order elimination rate constant k where t 1/2 ϭ 0.693/k. The area under the plasma concentration-time curve, determined by the trapezoidal rule, was extrapolated to infinity using k to determine AUC 0 -ϱ . Plasma clearance and bioavailability were calculated from AUC 0 -ϱ , dose, and k.
Identification of Metabolites. LC-MS of metabolites. Urine samples were vortex-mixed, centrifuged, and transferred to the autosampler for injection. Plasma samples were extracted by mixing with a 2ϫ volume of acetonitrile, centrifuged, and concentrated to approximately the original volume. Hepatocyte and liver slice samples were extracted by mixing with an equal volume of acetonitrile, centrifuged and diluted with an equal volume of 0.2% formic acid.
Electrospray LC-MS/MS analysis was performed on a Thermo Finnigan LCQ mass spectrometer (Thermo Fisher Scientific, Waltham, MA), with a spray voltage of 5.0 kV and a capillary temperature of 225°C. Product ion spectra were generated at a relative collision energy of 40%. Full-scan spectra were acquired in the positive ion mode. There was also in-line UV detection with a Finnigan Surveyor PDA. Samples were introduced into the mass spectrometer source via a Supelco Discovery C18 column (2.1 ϫ 150 mm, 5 m), using a combination of mobile phase A (0.2% formic acid in water) and mobile phase B (10% isopropyl alcohol in acetonitrile) at a flow rate of 200 l/min. The following profile for mobile phase B was used: initial, 10%; 2 min, 10%; 22 min, 50%; 32 min, 90%; 36 min, 90%; 36.1 min, 10%; and 42 min (stop), 10%. Accurate mass measurements were obtained on a Micromass QToF-2/MS using positive ion electrospray, a resolution of 8500 full width at half-maximum, a cone voltage of 40 V, a collision energy of 25 V, and a lock mass of 311.0814 (protonated molecular ion of the sulfadimethoxine standard).
Isolation of M25. Urine from the individual dogs was pooled (approximately 300 ml) and applied directly to two Varian Mega Bond Elut C18 SPE columns, which were washed with water (approximately 60 ml each) and eluted with methanol (approximately 50 ml each). The combined eluate was evaporated to dryness, and the residue was reconstituted in 2.5 ml of wateracetonitrile (85:15). The sample was centrifuged, and the supernatant was fractionated on a Supelco Discovery C18 column (4.6 ϫ 250 mm, 5 m) using the same solvent system and gradient as described above. Fractions were collected in 15-s intervals from 5 to 35 min at a flow rate of 4.0 ml/min. Pooling of fractions for M25 was based upon purity and concentration as measured by LC-MS. After pooling, the solvent was evaporated, and the dried material was used for NMR analysis.
NMR analysis of M25. NMR spectra were recorded at 25.0°C on an Inova 500 MHz NMR spectrometer equipped with a pulsed-field gradient and a Nalorac MDG 500 3-mm probe (Varian Inc., Palo Alto, CA). for 1 H and ␦ 49 for 13 C. Two-dimensional NMR experiments including double quantum-filtered correlated spectroscopy, total correlation spectroscopy, heteronuclear single quantum coherence, and heteronuclear multiple-bond correlation were performed using Varian standard pulse sequences.
Molecular modeling of M25. Molecular modeling was performed using Maestro and MacroModel software (2008; Schrodinger LLC, New York, NY). For M25, an extensive conformational search was done using the mixed torsional/low-mode sampling procedure (2000 maximum steps), the OPLS2005 forcefield, the GBSA continuum aqueous solvation treatment, and complete energy minimization to convergence. With use of the identified M25 global minimum energy structure and an equivalently minimized structure for LSN60645, NMR shielding tensors were calculated using the ab initio program Gaussian 03 (Frisch et al., 2004) by density functional theory (B3LYP functional, the 6 -31ϩϩG(d,p) basis set, and the GIAO method) and without geometry optimization. From these, the calculated chemical shift difference for the pyridinyl proton in M25, compared with LSN60645, was estimated by the difference in the calculated isotropic magnetic shielding tensor for the equivalent proton in each molecule.
Quantitation of M25. M25 was quantitated in dog urine by LC-UV using the analog, LSN60645, as a surrogate analytical standard, because both compounds contained the same diagnostic diimidazopyridine chromophore. The LC-UV response at 311 nm was selective for M25 and LSN60645. LC-UV detection was performed on a Waters 996 photodiode array detector (220 -500 nm). Chromatography was performed using a Supelco Discovery C18 column (2.1 ϫ 150 mm, 5 m) with the same mobile phase conditions as described above under LC-MS of Metabolites for the quantitation of M25 in urine and an isocratic delivery of mobile phase B for the quantitation of LSN60645 in an aqueous solution matrix. The calibration range was 8 to 1000 ng/ml. LSN60645 and M25 both contained the same chromophore responsible for absorbance at ϭ 311 nm, and, consequently, their extinction coefficients at this wavelength were assumed to be the same. Because a standard was available for LSN60645, its extinction coefficient was determined by measuring its absorbance at a known concentration in chloroform at max ϭ 311 nm on a Spectra Max Plus spectrophotometer (Molecular Devices, Sunnyvale, CA) with 1-cm quartz cuvettes. The extinction coefficient for LSN60645 was calculated to be 12,741 M Ϫ1 cm
Ϫ1
.
Results
Pharmacokinetics of LY2456322. The pharmacokinetics of LY654322 were investigated in rats and dogs. After intravenous administration, mean values for plasma clearance and terminal half-life were 75 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 and 2 h, respectively, in rats and 33 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 and 5 h, respectively, in dogs. After oral administration, the bioavailability in rats and dogs was 74 and 33%, respectively.
LC-MS/MS of LY654322. The LC-MS/MS spectrum of LY654322 is shown in Fig. 2 . MH ϩ at m/z 563 undergoes a facile loss of H 2 O, probably through amide-imidic acid tautomerization at either of the two peptide linkages followed by intramolecular condensation to the 
LC-MS of LY654322, M25, and its related metabolites
rp, dp, ru, du, rs, ds, hh
ru, du rp, rat plasma; dp, dog plasma; ru, rat urine; du, dog urine; rs, rat liver slice; ds, dog liver slice; hh, human hepatocyte. Table 1 . Metabolism of LY654322. Plasma and urine samples from rats and dogs dosed with LY654322 were profiled by LC-UV and LC-MS/MS. LY654322 was cleared by urinary excretion of parent and metabolism. Sixteen metabolites were identified between rats and dogs collectively, with considerable overlap occurring between species. Metabolism of the parent was related to the following structural regions: (A) aliphatic and N-oxidation, (B) aliphatic and aromatic oxidation, and (C) amide hydrolysis (Fig. 1) . Among the downstream metabolites of LY654322 was M25, which was identified only in the urine of rats and dogs. M25 was not identified as a metabolite in rat or dog liver slices or human hepatocytes, nor was it detected as an impurity in parent drug in incubations in which liver slices and hepatocytes were absent. Taken together, these results indicated that M25 was an authentic urinary metabolite of LY654322. M25 was structurally unusual and subject to detailed investigation.
Characterization of M25. LC-MS analysis of rat and dog urine identified M25 as eluting after the parent on reverse-phase chromatography (Fig. 3) . Furthermore, its MH ϩ at m/z 598 exceeded the MH ϩ of the parent by 35 Da (Table 2 ) and was not the product of direct phase 2 conjugation as detailed below. Given its increased lipophilicity and its mass difference compared with the parent, it was evident that the metabolic pathway to M25 was not straightforward. Valuable insight into the structure of M25 was gained through a series of MS n experiments (Fig. 4) . 
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at ASPET Journals on June 6, 2017 dmd.aspetjournals.org nyl)-1-methyl-2-oxo-2-pyrrolidinyl substructure. The complementary ion to m/z 220 at m/z 160 was fragmented, and, on this occasion, there was only a weak loss of HCN, indicating that m/z 160 was very stable and probably aromatic. The structure of M25 was further probed with the application of accurate mass MS and MS/MS experiments, which ascribed what was envisioned to be the central core to the formula C 7 H 5 N 5 (neutral molecule), a composition requiring eight double bond equivalents (Table 1) . To rationalize the existing data, the following structure was proposed: two symmetrically disposed N-[1-(4-fluorophenyl)-1-methyl-2-oxo-2-pyrrolidinyl] substituents to a fused diimidazopyridine. Because the diimidazopyridine substructure was critical to the characterization of M25, it was used to interrogate the Lilly database for a structural precedent. The hit, LSN60645, a diimidazopyridine analog, was fortuitous, because it served as a conduit to a series of informative UV and NMR experiments.
The UV spectrum of the parent was characterized by a single max at 213 nm (Fig. 5A) . M25, on the other hand, displayed two max values: one at 208 nm, comparable with the parent, and another with a bathochromic shift at 311 nm, consistent with extensive conjugation (Fig. 5B) . The UV spectra of M25 matched that of the standard LSN60645, supporting the diimidazopyridine substructure of the central core.
NMR was critical in reconciling the connectivity of the proposed heterocycle core to other substructures of parent in the metabolite. Although the molecular mass of M25 was 35 Da higher than that of LY654322, the 1 H NMR spectrum of the metabolite was strikingly less complex than that of the parent (see Fig. 6 for the aromatic region of LY654322 and M25 and Table 3 for the chemical shift assignments). The aromatic region of the proton NMR spectrum of M25 consisted of only four resonances, two of which (␦ 7.39 br dd; ␦ 7.27 br t) were assigned to the 4-flurophenyl substituent analogous to the parent compound (Table 3) . Furthermore, the recurrence of the pyrrolidinyl protons and their respective carbons in M25 compared with parent supported the retention of the 1-(4-flurophenyl)-1-methyl-2-oxo-2-pyrrolidinyl substructure in M25 (Table 3 ). The mutually cou- (Table 3 ) and the fact that the intensity of the singlet proton at ␦ 6.92 is approximately one-fourth of the equivalent 4-fluorophenyl protons at ␦ 7.39 or ␦ 7.27 revealed that M25 possesses an element of symmetry. Because the UV spectrum of M25 was very similar to that of LSN60645, a diimidazo pyridinyl derivative, the proton NMR spectrum of M25 was compared with that of LSN60645 (Fig. 6 ). The comparison revealed that both spectra showed a singlet resonance with 2 proton intensity in the range ␦ 8.2 to 8.3, which was assigned to the magnetically equivalent 2 imidazolyl protons of a highly conjugated system. However, the pyridinyl proton (H-19) that resonated at ␦ 8.06 in LSN60645, a normal chemical shift associated with its chemical environment, appeared with a pronounced up-field shift at ␦ 6.92 (⌬␦ ϭ 1.14) in M25.
To rationalize the NMR of M25, molecular modeling experiments were performed. A conformational search resulted in a global minimum energy structure (Fig. 7) and other conformations within 2.6 kcal/mol of the global minimum (data not shown), all of which positioned the pyridinyl proton perpendicular to the two fluorophenyl rings. Oriented as such, this proton should experience significant shielding due to the aromatic ring current and a pronounced diamagnetic shift. Indeed, calculating the pyridinyl proton chemical shift difference between M25 (in the illustrated conformation) and LSN60645 by ab initio quantum mechanical methods gave a value ⌬␦ ϭ 0.82, comparable to the up-field shift that was experimentally observed. This finding supports the contention that in M25 the ring current from the phenyl groups in close proximity to the pyridinyl proton should perturb its chemical shift up-field, with respect to the same proton in LSN60645.
Identification of Metabolites Related to M25. M2. M2 was identified in the plasma and urine of rats and dogs (Table 2) Urinary Excretion of M25 in Rats and Dogs. Given the identification of M25 in the urine of both rats and dogs and the similar UV spectra of M25 and LSN60645 in the region ϭ 308 to 312 nm, UV spectroscopy was exploited as a tool to quantitate M25 in urine and determine the extent of urinary excretion in animals. In dog urine, the 
at ASPET Journals on June 6, 2017 dmd.aspetjournals.org chromatographic peak for M25 was well isolated and the UV range was very selective, allowing M25 to be quantitated and its urinary disposition to be assessed at 0.3% of the dose in 24 h. Although M25 was identified in rat urine, it could not be quantitated because of high chromatographic interference.
Discussion
The preclinical pharmacokinetics and metabolism of LY654322 were determined as part of late-stage discovery characterization. The pharmacokinetics were characterized in rats and dogs as having high clearance comparable with hepatic blood flow in both species (Davies and Morris, 1993) . The compound was extensively metabolized. One of the metabolites identified during the course of these studies was M25, excreted in rat and dog urine, which had LC-MS/MS and UV properties that sparked our interest. The MS n fragmentation sequence of M25 (m/z 598 3 379 3 160 3 133) coupled with the bathochromic shift in its max compared with the parent indicated that M25 resulted from substantial molecular modification of LY654322. NMR 
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at ASPET Journals on June 6, 2017 dmd.aspetjournals.org characterization of M25 and molecular modeling substantiated the dimerization of two imidazo fragments from the parent with endogenous C-atom incorporation to afford a diimidazopyridine analog with a pyridinyl plane of symmetry. The initial step in the metabolism of LY654322 to M25 is proposed to occur through the hydrolysis of the peptide linker to afford the aminoimidazole M2, which was identified in the plasma and urine of both rats and dogs. Hydrolysis was catalyzed in the liver based on the identification of M2 in rat and dog liver slices and human hepatocytes. M19, the complementary carboxylic acid in the peptide linkage to M2, as well as the downstream M2 glucuronides, M23 and M24, supported the occurrence of M2.
The organ(s), subcellular compartment(s), and conditions that contribute to the formation of M25 from M2 are not known. Although M2 was formed in liver slices and hepatocytes, M25 was not a metabolite in vitro. It is possible that in vitro conditions were not optimized for the formation of M25 from M2 or the formation of M25 takes place extrahepatically.
The subsequent incorporation of the M2 substructure in M25 is envisioned in the metabolic sequence described in Fig. 8 . M2 tautomerizes to the imine, which undergoes nucleophilic attack by another aminoimidazole molecule to form the intermediate 1, which eliminates NH 3 to couple the two aminoimidazole subunits as the N-linked condensation product 2. Subsequently, the carbon of the central pyridinium heterocycle is added by formylation through a C-centered conjugate nucleophilic attack from one of the imidazo subunits to form 3. The latter is positioned for an entropically favored intramolecular nucleophilic attack from the carbon center of the other imidazo subunit to afford ring closure to 4 and ensuing aromatization with the loss of H 2 O to afford M25. None of the proposed intermediates 1 to 4 was identified as in vivo metabolites in rats or dogs.
The coupling, formylation, and cyclization steps in this metabolic scheme are noteworthy. First, the chemical condensation of aminoimidazoles described in the literature (Bredereck et al., 1964a,b) requires high temperatures (Ͼ100°C). The proposed dimerization of M2 is thought to proceed under physiological conditions, although the dimer (intermediate 2) was not detected in liver slices or hepatocytes. It is not known whether this process is enzyme-catalyzed. Second, although the carbon source in its cyclization is conjectural (vide infra), experiments were conducted to ensure that introduction of a single carbon in the formation of M25 was not an artifact of analysis or processing. In control experiments, formic acid in the mobile phase was replaced with acetic acid or ammonium acetate for LC-MS, and in both instances M25 was present to the same extent. In addition, urine samples were incubated in 1% formic acid, and no change in M25 was discerned. Taken together, results of these experiments supported M25 being an authentic metabolite derived from the incorporation of carbon from an endogenous source.
The proposed C-formylation in the formation of M25 is based on precedence in the literature for N-and C-formylation and invokes N 10 -formyltetrahydrofolate as a carbon source. N-Formylation in the metabolism of xenobiotics is an uncommon pathway. It has been described for aromatic (Santti and Hopsu-Havu, 1968; Gothoskar et al., 1979; Tjørnelund et al., 1991) and aliphatic (Mutlib et al., 2002; Obach et al., 2006) at ASPET Journals on June 6, 2017 dmd.aspetjournals.org synthesis of purines is well recognized, being mediated by N 10 -formyltetrahydrofolate as the carbon source (Zhang et al., 2008) . C-Formylation, as a biotransformation, has very little precedence in the literature; one example describes the formation a C-formyl secondary metabolite of phencyclidine mediated through an enamine (Zhao et al., 1991) . The reaction was catalyzed by a mitochondrial enzyme with either N 5 -or N 10 -formyltetrahydrofolate as the carbon source. The C-formylation of intermediate 2 through a conjugate addition (Fig. 8 ) appears analogous to that described for phencyclidine. In this case, however, the reaction is driven forward by cyclization and aromatization steps to form M25, interestingly analogous to the N-centered formylation and additional steps in purine biosynthesis (Zhang et al., 2008) .
In summary, LY654322 was metabolized in rats and dogs to M25, which was characterized by LC-MS n , UV, NMR, and molecular modeling, as an unusual diimidazopyridine. The formation of M25 was rationalized by an initial amide hydrolysis of LY654322 to the aminoimidazole M2, which underwent dimerization, C-formylation, cyclization, and aromatization.
